Mariam E. Morris
2017
In 2017, Mariam E. Morris earned a total compensation of $318.7K as Chief Financial Officer at Avalo Therapeutics, a 26% decrease compared to previous year.
Compensation breakdown
| Option Awards | $16,798 |
|---|---|
| Salary | $295,200 |
| Other | $6,718 |
| Total | $318,716 |
Morris received $295.2K in salary, accounting for 93% of the total pay in 2017.
Morris also received $16.8K in option awards and $6.7K in other compensation.
Rankings
In 2017, Mariam E. Morris' compensation ranked 13,186th out of 14,666 executives tracked by ExecPay. In other words, Morris earned more than 10.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 13,186 out of 14,666 | 10th |
Division Manufacturing | 5,188 out of 5,768 | 10th |
Major group Chemicals And Allied Products | 1,881 out of 2,074 | 9th |
Industry group Drugs | 1,568 out of 1,730 | 9th |
Industry Pharmaceutical Preparations | 1,210 out of 1,329 | 9th |
Source: SEC filing on April 5, 2018.
Morris' colleagues
We found five more compensation records of executives who worked with Mariam E. Morris at Avalo Therapeutics in 2017.
2017
Uli Hacksell
Avalo Therapeutics
Chief Executive Officer
2017
Ronald Marcus
Avalo Therapeutics
Chief Medical Officer
2017
John Kaiser
Avalo Therapeutics
Chief Executive Officer
2017
Peter Greenleaf
Avalo Therapeutics
Chief Executive Officer
2017
Robert Moscato
Avalo Therapeutics